Quantcast
Last updated on April 19, 2014 at 8:45 EDT

Wound Management Technologies, Inc. Announces Negotiations to Acquire BioPharma Management Technologies, Inc.

December 11, 2008

FORT WORTH, Texas, Dec. 11 /PRNewswire-FirstCall/ — Wound Management
Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it is
exploring a potential acquisition of BioPharma Management Technologies, Inc.,
a company that has recently launched the development of topical pain
management products. “While we have been focusing this year on expanding
market penetration of our CellerateRx(R) products, we also have been working
to expand our current product portfolio. We believe that the science behind
BioPharma’s product development shows potential and creates market synergies
with our current products,” says Scott Haire, Wound Management Technologies’
CEO. “We believe that BioPharma’s products will provide a broad application
across several medical specialities. We are not aware of any currently
available products in the market that provide the benefits we expect
BioPharma’s unique formulation to deliver.”

BioPharma is developing a topical pain management product targeting the
growing pain management market place. “Based on our research, we believe that
this product will provide a broad application across several medical
specialities while supplying a good safety profile, expanded dosing range and
flexibility, and should create and maintain a moist environment conducive to
drug absorption and reduction of irritation at the application site. All year
we have focused on Cellerate as a one-of-a-kind product and adding an
additional company and product mix should make us a leader in the wound
industry and related healthcare markets,” states Scott Haire, CEO of Wound
Management Technologies. “Also this should significantly increase our
revenues in 2010 in all areas of wound care.”

CellerateRx(R) is exclusively distributed by Wound Care Innovations, a
subsidiary of Wound Management Technologies. It is a one-of-a-kind, patented,
advanced wound care collagen product and is FDA cleared for acute and chronic
wounds which include but are not limited to: diabetic ulcers, pressure ulcers
stage I-IV, venous stasis ulcers, ulcers due to arterial insufficiency,
surgical wounds, traumatic wounds, superficial wounds, and 1st and 2nd degree
burns. “In 2008, the company has focused on providing additional
evidence-based data and has been published in two major wound care
publications as well as had a featured speaker at a major wound care
conference. Our efforts in 2008 serve to boost customer confidence and will
contribute to market success in 2009,” states Cathy Bradshaw, President of
Wound Care Innovations. “Adding BioPharma’s future product mix has the
potential to make us a leader in wound care and other medical management
areas.”

About Wound Management Technologies, Inc.:

Wound Management Technologies, Inc. (WNDM), with its corporate
headquarters in Fort Worth, Texas, markets and distributes wound care products
to the healthcare market under patented technology licensed to the Company.
The Company is positioned and seeks to be a leading provider of wound care
products. For more information on the Company please visit the Company’s
Website at www.Celleraterx.com .

“Safe Harbor” Statement: Under The Private Securities Litigation Reform
Act of 1995: The statements in the press release that relate to the company’s
expectations with regard to the future impact on the company’s results from
new products in development are “forward-looking statements,” within the
meaning of the Private Securities Litigation Reform Act of 1995. Since this
information may contain statements that involve risk and uncertainties and are
subject to change at any time, the company’s actual results may differ
materially from expected results. This document may contain forward-looking
statements concerning the Company’s operations, current and future performance
and financial condition. These items involve risks and uncertainties such as
product demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, the ability to consummate and integrate
acquisitions, and other risks and uncertainties detailed in the Company’s SEC
filings. The Company undertakes no obligation to revise any of these
statements to reflect the future circumstances or the occurrence of
unanticipated events.

    Product Information                        Shareholder Relations
    Cathy Bradshaw                             Lucy Singleton
    President                                  Corporate Secretary
    954-315-9242                               817-820-7080

SOURCE Wound Management Technologies, Inc.


Source: newswire